

1 Original article

2 **Impact of vaccination on the presence and severity of**
3 **symptoms of hospitalised patients with an infection by**
4 **the Omicron variant (B.1.1.529) of the SARS-CoV-2**
5 **(subvariant BA.1).**

6
7 Guillaume Beraud¹, Laura Bouetard^{2,3}, Rok Civljak^{4,5}, Jocelyn Michon⁶, Necla Tulek⁷, Sophie
8 Lejeune⁸, Romain Millot¹, Aurélie Garchet-Beaudron⁹, Maeva Lefebvre^{10,11}, Petar Velikov¹²,
9 Benjamin Festou¹³, Sophie Abgrall^{2,3}, Ivan Kresimir Lizatovic⁴, Aurélie Baldolli⁶, Huseyin
10 Esmer⁷, Sophie Blanchi⁹, Gabrielle Froidevaux¹⁰, Nikol Kapincheva¹², Jean-François
11 Faucher^{13,14}, Mario Duvnjak^{15,16}, Elçin Afşar¹⁷, Luka Švitek^{15,16}, Saliha Yarimoglu¹⁸, Rafet
12 Yarimoglu¹⁸, Cécile Janssen¹⁹, Olivier Epaulard⁸.

13
14 1: Infectious disease department, University Hospital of Poitiers, Poitiers, France.

15 2: APHP, Hôpital Antoine Béclère, Service de Médecine Interne, Clamart, France.

16 3: Université Paris-Saclay, UVSQ, INSERM U1018, CESP, Le Kremlin-Bicêtre, France.

17 4: University Hospital for Infectious Diseases "Dr. Fran Mihaljevic", Zagreb, Croatia.

18 5: University of Zagreb School of Medicine, Zagreb, Croatia.

19 6: Department of Infectious diseases, University Hospital of Caen, Caen, France.

20 7: Atılım University, Department of Infectious Diseases and Clinical Microbiology

21 Ankara Training and Research Hospital, Turkey.

22 8: Infectious diseases, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France.

23 9: Infectious Disease Department, CH, Le Mans, France.

24 10: Infectious Disease Department, Centre for Prevention of Infectious and Transmissible
25 Diseases, CHU Nantes, Nantes, France.

26 11: INSERM UIC 1413 Nantes University, Nantes, France.

27 12: Infectious Disease Hospital "Prof. Ivan Kirov", Medical University of Sofia, Bulgaria.

28 13: CHU Limoges, Department of Infectious Diseases and Tropical Medicine, Limoges

29 France

30 14: INSERM U1094, Limoges, France.

31 15: Clinic for Infectious Diseases, University Hospital Centre Osijek, Osijek, Croatia.

32 16: Faculty of Medicine Osijek, J. J. Strossmayer University of Osijek, Osijek, Croatia.

33 17: Atılım University, Vocational School of Health Services, Ankara, Turkey.

34 18: Karaman Training and Research Hospital, Turkey.

35 19: Infectious Disease Unit, Centre Hospitalier Annecy Genevois, Annecy, France.

36

37 **Corresponding author:**

38 Guillaume BERAUD

39 Infectious disease department,

40 University Hospital of Poitiers 2, rue de la Milétrie 86000 POITIERS

41 France

42 beraudguillaume@gmail.com

43 +33 (0)6.82.75.27.26

44

45

46 **Abstract**

47

48 **Objectives:**

49 The emergence of SARS-CoV-2 variants raised questions over the extent to which vaccines
50 designed in 2020 have remained effective. We aimed to assess whether vaccine status was
51 associated with the severity of Omicron SARS-CoV-2 infection in hospitalised patients.

52 **Methods:**

53 We conducted an international, multicentric, retrospective study in 14 centres (Bulgaria,
54 Croatia, France, Turkey). We collected data on patients hospitalised ≥ 24 hours between
55 01/12/2021 and 03/03/2022, with PCR-confirmed infection at a time of exclusive Omicron
56 circulation, with hospitalisation related or not to the infection. Patients who had received
57 prophylaxis by monoclonal antibodies were excluded. Patients were considered fully
58 vaccinated if they had received at least 2 injections of either mRNA and/or ChAdOx1-S, or 1
59 injection of Ad26.CoV2-S vaccines.

60 **Results:**

61 Among the 1215 patients (median [IQR] age 73.0 [57.0; 84.0]; 51.3% males), 746 (61.4%)
62 were fully vaccinated. In multivariate analysis, being vaccinated was associated with lower
63 28-day mortality (RR=0.50 [0.32-0.77]), ICU admission (R=0.40 [0.26-0.62], and oxygen
64 requirement (RR=0.34 [0.25-0.46]), independently of age and comorbidities. When co-
65 analysing these Omicron patients with 948 Delta patients from a study we recently
66 conducted, Omicron infection was associated with lower 28-day mortality (RR=0.53 [0.37-
67 0.76]), ICU admission (R=0.19 [0.12-0.28], and oxygen requirements (RR=0.50 [0.38-0.67]),
68 independently of age, comorbidities and vaccination status.

69 **Conclusions:**

70 mRNA- and adenovirus-based vaccines have remained effective on severity of Omicron
71 SARS-CoV-2 infection. Omicron is associated with a lower risk of severe forms,
72 independently of vaccination and patient characteristics.

73

74 **Keywords:** SARS-CoV-2; omicron; vaccine, breakthrough infection, severity

75 Introduction

76 First identified in Botswana and South Africa in November 2021, the Omicron (B.1.1.529)
77 variant of concern (VOC) of SARS-CoV-2 replaced the Delta (B.1.617.2) VOC globally, and
78 became virtually the only circulating variant in most countries in December 2021 and
79 January 2022. Between December 2021 and April 2022, it was responsible for the most
80 massive waves so far of SARS-CoV-2 infection in Europe, North America, China and Japan
81 since the beginning of the pandemic (ECDC 2022). The range of Omicron VOC waves is
82 considered to be related to increased infectivity and to immune escape from neutralising
83 antibodies resulting from previous SARS-CoV-2 infection, vaccination, or both (Syed et al.
84 2022; Cui et al. 2022).

85 In most European countries, the unprecedented numbers of SARS-CoV-2 infections
86 observed during these Omicron waves were associated with a decreased case-fatality rate
87 compared with the Delta VOC (Nyberg et al. 2022; Johnson et al. 2022; Auvigne et al. 2022).
88 Whether related to an intrinsically lower risk of severe COVID-19 associated with Omicron
89 infection, or to the high vaccine coverage in most of these countries, this VOC calls into
90 question the impact of vaccination at both the individual and the populational level.
91 Meanwhile, the picture provided by the aforementioned studies is incomplete, as most milder
92 cases will not be admitted to hospital or even be diagnosed.

93 We aimed to determine the extent to which vaccination was still associated with protection
94 against severe forms of Omicron infection, by assessing whether such forms differed among
95 people hospitalised with SARS-CoV-2 infection when considering their vaccine status, as
96 well as other risk factors. We also explored the influence of VOC by coupling our data with
97 previously published data with the Delta variant, and using the same methodology.

98

99 **Methods**

100 We carried out a retrospective, multicentre study across 14 hospital centres from four
101 countries, namely Bulgaria (Sofia), Croatia (Olsijek, Zagreb), France (Annecy, Paris/Béclère,
102 Caen, Grenoble, Le Mans, Limoges, Nantes, Poitiers) and Turkey (Ankara and Karaman).
103 Hospitalised patients with a PCR-confirmed SARS-CoV-2 infection from December, 1st 2021
104 to March, 3rd 2022 (i.e., when the Omicron (B.1.1.529) variant [subvariant BA.1] was
105 virtually the only circulating SARS-CoV-2 variant in these countries) were included
106 chronologically regardless of the indication for admission, the objective being to include at
107 least the first 50 to 100 patients per centre. Patients were considered as infected by the
108 Omicron VOC either through mutation screening, or because it was the only variant
109 circulating at that time in the area according to the virologist from each centre.

110 A patient was considered fully vaccinated if he/she had received at least either one injection
111 of the Ad26.CoV2-S vaccine (Janssen), or two injections of the ChAdOx1-S vaccine
112 (AstraZeneca) and/or RNA vaccines (tozinameran [Pfizer/BioNTech] and elasomeran
113 [Moderna]), and with the last injection given at least 14 days before the date of PCR.
114 Vaccinated and unvaccinated patients were included concurrently, according to order of
115 hospitalisation in the participating centre.

116 Data were anonymously collected with a form similar to the one used in a recent study on
117 SARS-CoV-2 Delta infection [1], providing similar variables (Supplementary material, Table 1
118 and 2), with the exception of antiviral treatments which were not available at the time data
119 were collected for the Delta study. The ethics committee of the French-speaking Society of
120 Infectious Diseases (SPILF) (IRB00011642) gave its approval for the study (N°2022-0101),
121 which was declared to the French National Commission for Informatics and Liberties (CNIL
122 MR004: n°2224742).

123 **Statistical analysis**

124 The cohort population was described according to vaccination status with qualitative
125 variables as counts (percentage) and frequency distributions compared with the Chi square
126 test or Fisher's exact test when appropriate. Continuous variables were expressed as
127 median (1st quartile; 3rd quartile) and differences were tested with the independent t-test for
128 normally distributed variables or otherwise the Mann-Whitney U test. Factors associated with
129 severe forms of infection defined by three outcomes (requirement for oxygen, ICU admission
130 and death at day 28) were assessed. Univariate and multivariate logistic regressions based
131 on general linear models were performed with a stepwise variable selection according to the
132 Akaike Information Criterion (Akaike 1973). To assess the impact of comorbidities and
133 vaccination, we selected all the potential risk factors for severe outcome presented in Table
134 3 for the multivariate model (Table 4 and Supplementary materials). Even though some data
135 were missing at random, in many cases this was because they did not exist. As an example,
136 missing CT-scan results could have been due to the fact that patients were too severe to
137 receive a CT scan before high flow nasal oxygen or mechanical ventilation, or to the fact that
138 the patient was only mildly ill and went back home without any oxygen requirement. To
139 manage Missing data Not At Random (MNAR), multivariate analysis was initially performed
140 only on the dataset with complete cases, after which the model was applied to the full
141 dataset (Jakobsen et al. 2017). Results are presented based on the full dataset, as they
142 were similar to the analysis restricted to the complete case dataset. In addition, a
143 multivariate analysis was similarly carried out on the dataset of vaccinated patients only, so
144 as to independently assess the weight of comorbidities among vaccinated patients, taking
145 into account the influence of the time elapsed since the most recent injection. Interactions
146 were systematically searched and mentioned if found. Finally, this cohort of Omicron-
147 infected patients was merged with a cohort of Delta-infected patients recently published
148 (Epaulard et al. 2022), and an analysis was performed taking into account the variant of
149 concern.

150 All statistical analyses were performed with R version 4.1.2. Packages readxl, Amelia, xlsx,
151 ggplot2, MASS, VIM were used.

152 Results

153 We included 1215 hospitalised patients, among whom 746 (61.4%) were fully vaccinated
154 and 469 (38.6%) were not vaccinated at all. Main characteristics of both groups are
155 described in Table 1.

156 Among vaccinated patients with complete information on their vaccine history (n=674), most
157 were vaccinated with Pfizer vaccines only (n=431, 63.9%) or a mix of the two mRNA
158 vaccines (n=91, 13.5%) whereas a few had had a mix of mRNA and adenovirus vaccines
159 (53, 7.9%), or only Moderna vaccines (n=52, 7.7%), AstraZeneca vaccines (n=23, 3.4%) or
160 Janssen vaccines (n=15, 2.2%). Three hundred and ninety-five patients (53.7% of the
161 vaccinated) had received more than 2 doses. The median time from the last vaccine dose
162 was 113.0 days [IQR 64.0-178.2].

163 **Characteristics of the SARS-CoV-2 infection according to vaccine status**

164 In bivariate analysis, vaccinated patients were slightly older, more frequently male, and more
165 frequently presented with certain comorbidities (respiratory disease, hematologic
166 malignancy, immunodepression), although they did not differ with unvaccinated patients in
167 terms of median number of comorbidities.

168 Notwithstanding which, unvaccinated patients had more severe SARS-CoV-2 infections
169 (Table 2): they were more frequently admitted because of COVID-19 instead of being
170 admitted for another cause with an incident diagnosis of an asymptomatic SARS-CoV-2
171 infection; their lung involvement was more extended on CT scan; they more frequently
172 required oxygen supplementation, at higher flow, and for a longer duration; they more
173 frequently required high-flow oxygen therapy, and immunomodulatory therapy such as
174 steroids or tocilizumab. The protective effect of vaccination predominated at an older age
175 (Figure 1).

176 **Factors associated with severity**

177 Three outcomes were considered: the need to receive oxygen, the need to be admitted to an
178 ICU, and death at day 28. In bivariate analysis, older age, male gender and most
179 comorbidities (as well as having at least 1 comorbidity, or a higher number of comorbidities)
180 were significantly associated with one or several negative outcomes. Conversely,
181 vaccination was protective against these three outcomes (Table 3).

182 In multivariate analysis, the protective effect of vaccination persisted with regard to need for
183 oxygen, need for ICU admission, and risk of death, and it attenuated and practically
184 discarded the negative impact of many comorbidities (Table 4). Older age, solid or
185 haematological cancer and kidney failure remained independent risk factors for a more
186 severe outcome, notably death. Pulmonary diseases tended to negatively impact the
187 outcome but only regarding need for oxygen was the impact significant. A past history of
188 SARS-CoV-2 infection tended to be protective against death and the need for ICU but with
189 large confidence intervals that excluded significance.

190 **Influence of the variant of concern (Delta vs. Omicron)**

191 Patients infected by the Omicron VOC presented less severe infection, either vaccinated or
192 unvaccinated, compared to patients infected by the Delta VOC.

193 In bivariate analysis (Table 5 and 6), whether vaccinated or not, Omicron-infected patients
194 were significantly (or at least presented a trend) less hospitalised for COVID-19 (significantly
195 among those vaccinated), had lower median CRP (significantly among those vaccinated),
196 had less extended lung lesion on CT scan (significantly among those unvaccinated), less
197 frequently required oxygen supplementation, high-flow oxygen therapy, steroid therapy or
198 tocilizumab (significantly among both vaccinated and unvaccinated), less frequently required
199 to be admitted in ICU (both vaccinated and unvaccinated), and had lower 28-day mortality
200 (among those vaccinated).

201 In multivariate analysis (Table 7), Omicron infection, compared to Delta, was associated with
202 less need for oxygen therapy, less ICU admission, and fewer deaths, while vaccination and

203 a past history of SARS-CoV-2 infection were also protective. Only male gender, older age,
204 kidney failure, immunosuppression and solid cancer were still risk factors for mortality.
205 The interaction between immunosuppression and vaccination suggests that the protective
206 effect of vaccination on the need for ICU is decreased among the immunosuppressed. The
207 interaction between vaccination and a past history of SARS-CoV-2 infection suggests a
208 lesser benefit of vaccination among patients having previously had SARS-CoV-2 infection.
209

210 Discussion

211 Despite the fact that Omicron emerged as a new VOC at the end of 2021, our results show
212 that vaccines designed in early 2020 still protect from severe forms. This protection persists
213 even, if not mostly, in older patients, as well as patients with comorbidities. Our study also
214 confirms that Omicron is less associated with severe forms than Delta, independently from
215 the known risk factors and from vaccine status. Complementarily, vaccine-induced protection
216 prevails, whether the VOC is a Delta or Omicron. However, greater age, kidney failure, and
217 solid or haematological cancer are still associated with mortality, whereas vaccination can
218 limit the influence of many risk factors.

219 The large cohort of 2167 patients obtained by merging our two cohorts highlights the fact
220 that the VOC is a risk factor in itself, with a greater risk of severe form associated with Delta
221 rather than Omicron, but also highlights the impact of past history of SARS-CoV-2 infection.
222 Previous SARS-CoV-2 infection protected from the need for oxygen or ICU in the Delta
223 cohort, but only with a non-significant trend toward lower mortality (Epaulard et al. 2022). A
224 similar but likewise non-significant trend (for the three outcomes) was observed in the
225 current study on Omicron. That said, the whole cohort provided sufficient power to show a
226 significant influence of a past SARS-CoV-2 infection regarding mortality, need for ICU or
227 need for oxygen.

228 Our results regarding the positive impact of vaccination on the SARS-CoV-2 infection are in
229 line both with previous studies on previous variants (particularly Delta (Epaulard et al. 2022;
230 Katikireddi et al. 2022; Harder et al. 2021)) and Omicron (Katikireddi et al. 2022; Brosh-
231 Nissimov et al. 2022). Some of these studies evidenced a marked decrease of vaccine
232 efficacy toward SARS-CoV-2 infection, but conserved efficacy regarding severe infection
233 and death. Most of the studies included patients even if they were not hospitalised; the fact
234 that we observed this protection even among patients hospitalised for Covid-19 (compared
235 to those with an incidental SARS-CoV-2 infection with no clinical Covid-19) is a strong
236 argument confirming the benefits of the vaccine.

237 Our observation regarding the lower risk of severe forms with Omicron infection compared
238 with Delta is in accordance with the current literature. Indeed, previous studies concluded
239 that Omicron was associated with less severe infections (Nyberg et al. 2022; Kahn et al.
240 2022). However, these studies were carried out at the populational level, where a large
241 number of asymptomatic or mild cases could have gone undetected, thereby diluting the
242 power to detect severe cases. Moreover, Delta and Omicron waves were not
243 contemporaneous, and have spread in potentially very different populations in terms of
244 vaccine coverage, past history of SARS-CoV-2 infection, etc. Such differences in the
245 populations could generate differences misattributed to the virus. However, with a
246 multivariate analysis applied to two cohorts with the same design, our study was able to
247 decouple the effect of Omicron from vaccination, and consequently confirmed that it
248 produces less severe forms than Delta. Nonetheless, the lesser proportion of severe forms
249 with Omicron compared to Delta is not as marked among older people compared to the
250 general population (Auvigne et al. 2022). It could be related to the difference of age between
251 the Delta and the Omicron cohort, but only partially as the multivariate analysis showed an
252 effect independent between Age and VOC. Consequently, severe forms do exist with
253 Omicron and are not negligible. Consequently, the benefit of vaccination even among older
254 patients and patients with comorbidities is an important rationale for vaccine campaigns.
255 Studies showing the benefit of vaccination among specific subpopulations at risk also
256 question the necessity of booster doses. As an example, studies in hemodialysis patients
257 have confirmed a vaccine-induced protection proportional to the number of doses (Cheng et
258 al. 2022; Espi et al. 2022).

259 Our study presents some limitations, in particular missing data, mostly due to its
260 retrospective design; for that reason, some items were not taken into consideration in the
261 analysis such as vaccine type. Moreover, we included patients from four countries, and our
262 results may have been different if more countries (either European or not) had been
263 represented. In addition, we did not perform anti-Spike serology at admission; anti-Spike
264 antibody level has been shown to be associated with prognosis (Plüme et al. 2022; Sanghavi

265 et al. 2022), and it might have facilitated understanding of the severity of SARS-CoV-2
266 infection in some vaccinated subjects, in particular among immunosuppressed subjects who
267 could present lesser response to vaccines. In addition, availability of antiviral treatment was
268 not comparable between the Delta and the Omicron wave, which could have had an impact
269 on mortality.

270 The main strength of our study is the large number of highly phenotyped patients, from
271 several centres for several countries, making our conclusions probably valid for most
272 populations. In particular, vaccine status was individually checked, ensuring accurate
273 classification of patients. In addition, the inclusion period we chose corresponds to a phase
274 of homogeneous circulation of a unique variant, ensuring more precision to our conclusions.
275 Lastly, the fact that the data collection was aligned with the Delta study performed in 2021
276 enabled us to conduct with high validity the comparison between the two variants.

277 Our study has several implications. The fact that despite the immune escape by Omicron,
278 vaccination with the currently available vaccines still retains efficacy against severe
279 infections, should be remembered and widely publicised, to help the population at risk of
280 severe COVID-19 and their healthcare professionals to receive an additional dose.

281 Interestingly, if Omicron infection is less associated with severe COVID-19, it was also
282 shown to be more contagious than Delta infection (Syed et al. 2022; Cui et al. 2022); this
283 explains why many deaths were still observed during the BA-1 and BA-2 waves, the low
284 frequency of severe form being counterbalanced by the massive number of infections. This
285 observation undermines the statements describing Omicron as a step of SARS-CoV-2
286 toward a more “banal” coronavirus (Balloux et al. 2022; Callaway 2021; Gudina, Ali, et
287 Froeschl 2022), such as 229E, NL63, OC43 and HKU1, and is an argument to maintain high
288 vaccine coverage. Moreover, divalent mRNA vaccines have received market authorisation
289 by the European medicines agency (EMA 2022 for Wuhan SARS-CoV-2 and Omicron BA.1
290 SARS-CoV-2 on 01/09/2022), and by the Food and Drug Administration (FDA) of the USA
291 (FDA 2022 Wuhan SARS-CoV-2 and Omicron BA.4/5 on 31/08/2022); our results suggest
292 that patients with risk factors for severe Covid-19 should not wait for such vaccines before

293 receiving a boosting injection (such an injection being recommended 3 to 6 months after the
294 previous one), as currently available vaccines, targeting the Wuhan SARS-CoV-2 viral
295 sequence, still retain efficacy.

296 During the second quarter of 2022, new Omicron subvariants, BA.4 and BA.5, progressively
297 became predominant in Europe. Studies showed a decrease in the neutralisation activities of
298 antibodies elicited by vaccination (Wang et al. 2022) and of therapeutic monoclonal
299 antibodies (Takashita et al. 2022) toward them. New studies are needed to determine the
300 extent to which vaccination status, the number of vaccine doses and the timing of the last
301 injection bring protection against severe infections, in addition to the impact of the divalent
302 vaccines.

303

304 **Transparency declaration:**

305 • **Conflict of interest** : None of the authors have any conflict of interest to disclose.

306 • **Funding**: No external funding was received.

307 • **Acknowledgements**: Authors are indebted to Sami Kinikli and Metin Ozsoy for data
308 capture, and to Jeffrey Arsham for English editing.

309 • **Access to data**: Anonymized data and analysis files are available on request to the
310 corresponding author.

311 • **Contribution**:

312 Conceptualization: GB, OE

313 Methodology: GB, OE

314 Software: GB, OE

315 Validation : SA, NT, JFF, JM, ML, PV, CJ, RC

316 Formal Analysis: GB, OE

317 Investigation : GB, SA, NT, JM, JFF, SB, ML, PV, RC, MD, CJ, OE

318 Resources: not applicable

319 Data curation: All authors.

320 Writing – Original Draft: GB, OE

321 Writing – Review & Editing: SA, ML, NT, PV, JFF, JM, SB, CJ

322 Visualization: GB, OE

323 Supervision: GB, OE

324 Administration: GB, OE

325 Funding acquisition: not applicable

326

327

328

References

- Akaike, Hirotugu. 1973. « Information theory and an extension of the maximum likelihood principle ». In *2nd International Symposium on Information Theory*. Academiai Kiado.
- Auvigne, Vincent, Sophie Vaux, Yann Le Strat, Justine Schaeffer, Lucie Fournier, Cynthia Tamandjou, Charline Montagnat, Bruno Coignard, Daniel Levy-Bruhl, et Isabelle Parent du Châtelet. 2022. « Severe Hospital Events Following Symptomatic Infection with Sars-CoV-2 Omicron and Delta Variants in France, December 2021-January 2022: A Retrospective, Population-Based, Matched Cohort Study ». *EClinicalMedicine* 48 (juin): 101455. <https://doi.org/10.1016/j.eclinm.2022.101455>.
- Balloux, François, Cedric Tan, Leo Swadling, Damien Richard, Charlotte Jenner, Mala Maini, et Lucy van Dorp. 2022. « The Past, Current and Future Epidemiological Dynamic of SARS-CoV-2 ». *Oxford Open Immunology* 3 (1): iqac003. <https://doi.org/10.1093/oxfimm/iqac003>.
- Brosh-Nissimov, Tal, Khetam Hussein, Yonit Wiener-Well, Efrat Orenbuch-Harroch, Meital Elbaz, Shelly Lipman-Arens, Yasmin Maor, et al. 2022. « Hospitalized Patients with Severe COVID-19 during the Omicron Wave in Israel - Benefits of a Fourth Vaccine Dose ». *Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America*, juin, ciac501. <https://doi.org/10.1093/cid/ciac501>.
- Callaway, Ewen. 2021. « Beyond Omicron: What's next for COVID's Viral Evolution ». *Nature* 600 (7888): 204–7. <https://doi.org/10.1038/d41586-021-03619-8>.
- Cheng, Cho-Chin, Louise Platen, Catharina Christa, Myriam Tellenbach, Verena Kappler, Romina Bester, Bo-Hung Liao, et al. 2022. « Improved SARS-CoV-2 Neutralization of Delta and Omicron BA.1 Variants of Concern after Fourth Vaccination in Hemodialysis Patients ». *Vaccines* 10 (8): 1328. <https://doi.org/10.3390/vaccines10081328>.
- Cui, Zhen, Pan Liu, Nan Wang, Lei Wang, Kaiyue Fan, Qianhui Zhu, Kang Wang, et al. 2022. « Structural and Functional Characterizations of Infectivity and Immune Evasion of SARS-CoV-2 Omicron ». *Cell* 185 (5): 860-871.e13. <https://doi.org/10.1016/j.cell.2022.01.019>.
- ECDC. 2022. « Country overview report: week 32 2022 ». https://covid19-country-overviews.ecdc.europa.eu/key_epidemiological_indicators.html.
- EMA. 2022. « First Adapted COVID-19 Booster Vaccines Recommended for Approval in the EU ». <https://www.ema.europa.eu/en/news/first-adapted-covid-19-booster-vaccines-recommended-approval-eu>.
- Epaulard, Olivier, Sophie Abgrall, Maeva Lefebvre, Jean-François Faucher, Jocelyn Michon, Emilia Frentiu, Sophie Blanchi, et al. 2022. « Impact of Vaccination on the Symptoms of Hospitalised Patients with SARS-CoV-2 Delta Variant (B.1.617.1) Infection ». *Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases*, juin, S1198-743X(22)00332-9. <https://doi.org/10.1016/j.cmi.2022.06.019>.
- Espi, Maxime, Xavier Charmetant, Thomas Barba, Cyrille Mathieu, Caroline Pelletier, Laetitia Koppe, Elodie Chalencon, et al. 2022. « A Prospective Observational Study for Justification, Safety, and Efficacy of a Third Dose of mRNA Vaccine in Patients Receiving Maintenance Hemodialysis ». *Kidney International* 101 (2): 390–402. <https://doi.org/10.1016/j.kint.2021.10.040>.
- FDA. 2022. « COVID-19 Bivalent Vaccine Boosters ». <https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-bivalent-vaccine-boosters>.
- Gudina, Esayas Kebede, Solomon Ali, et Guenter Froeschl. 2022. « Omicron: A Blessing in Disguise? ». *Frontiers in Public Health* 10: 875022. <https://doi.org/10.3389/fpubh.2022.875022>.
- Harder, Thomas, Wiebe Külper-Schiek, Sarah Reda, Marina Treskova-Schwarzbach, Judith Koch, Sabine Vygen-Bonnet, et Ole Wichmann. 2021. « Effectiveness of COVID-19

- Vaccines against SARS-CoV-2 Infection with the Delta (B.1.617.2) Variant: Second Interim Results of a Living Systematic Review and Meta-Analysis, 1 January to 25 August 2021 ». *Euro Surveillanc: Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin* 26 (41). <https://doi.org/10.2807/1560-7917.ES.2021.26.41.2100920>.
- Jakobsen, Janus Christian, Christian Gluud, Jørn Wetterslev, et Per Winkel. 2017. « When and How Should Multiple Imputation Be Used for Handling Missing Data in Randomised Clinical Trials – a Practical Guide with Flowcharts ». *BMC Medical Research Methodology* 17 (1): 162. <https://doi.org/10.1186/s12874-017-0442-1>.
- Johnson, Amelia G., Avnika B. Amin, Akilah R. Ali, Brooke Hoots, Betsy L. Cadwell, Shivani Arora, Tigran Avoundjian, et al. 2022. « COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence - 25 U.S. Jurisdictions, April 4-December 25, 2021 ». *MMWR. Morbidity and Mortality Weekly Report* 71 (4): 132–38. <https://doi.org/10.15585/mmwr.mm7104e2>.
- Kahn, Fredrik, Carl Bonander, Mahnaz Moghaddassi, Magnus Rasmussen, Ulf Malmqvist, Malin Inghammar, et Jonas Björk. 2022. « Risk of Severe COVID-19 from the Delta and Omicron Variants in Relation to Vaccination Status, Sex, Age and Comorbidities - Surveillance Results from Southern Sweden, July 2021 to January 2022 ». *Euro Surveillanc: Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin* 27 (9). <https://doi.org/10.2807/1560-7917.ES.2022.27.9.2200121>.
- Katikireddi, Srinivasa Vittal, Thiago Cerqueira-Silva, Eleftheria Vasileiou, Chris Robertson, Sarah Amele, Jiafeng Pan, Bob Taylor, et al. 2022. « Two-Dose ChAdOx1 NCoV-19 Vaccine Protection against COVID-19 Hospital Admissions and Deaths over Time: A Retrospective, Population-Based Cohort Study in Scotland and Brazil ». *Lancet (London, England)* 399 (10319): 25–35. [https://doi.org/10.1016/S0140-6736\(21\)02754-9](https://doi.org/10.1016/S0140-6736(21)02754-9).
- Nyberg, Tommy, Neil M. Ferguson, Sophie G. Nash, Harriet H. Webster, Seth Flaxman, Nick Andrews, Wes Hinsley, et al. 2022. « Comparative Analysis of the Risks of Hospitalisation and Death Associated with SARS-CoV-2 Omicron (B.1.1.529) and Delta (B.1.617.2) Variants in England: A Cohort Study ». *Lancet (London, England)* 399 (10332): 1303–12. [https://doi.org/10.1016/S0140-6736\(22\)00462-7](https://doi.org/10.1016/S0140-6736(22)00462-7).
- Plūme, Jānis, Artis Galvanovskis, Sindija Šmite, Nadezhda Romanchikova, Pawel Zayakin, et Aija Linē. 2022. « Early and Strong Antibody Responses to SARS-CoV-2 Predict Disease Severity in COVID-19 Patients ». *Journal of Translational Medicine* 20 (1): 176. <https://doi.org/10.1186/s12967-022-03382-y>.
- Sanghavi, Devang K., Shivang Bhakta, Hani M. Wadei, Wendelyn Bosch, Jennifer B. Cowart, Rickey E. Carter, Sadia Z. Shah, et al. 2022. « Low Antispikes Antibody Levels Correlate with Poor Outcomes in COVID-19 Breakthrough Hospitalizations ». *Journal of Internal Medicine* 292 (1): 127–35. <https://doi.org/10.1111/joim.13471>.
- Syed, Abdullah M., Alison Ciling, Taha Y. Taha, Irene P. Chen, Mir M. Khalid, Bharath Sreekumar, Pei-Yi Chen, et al. 2022. « Omicron Mutations Enhance Infectivity and Reduce Antibody Neutralization of SARS-CoV-2 Virus-like Particles ». *Proceedings of the National Academy of Sciences of the United States of America* 119 (31): e2200592119. <https://doi.org/10.1073/pnas.2200592119>.
- Takashita, Emi, Seiya Yamayoshi, Viviana Simon, Harm van Bakel, Emilia M. Sordillo, Andrew Pekosz, Shuetsu Fukushi, et al. 2022. « Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants ». *The New England Journal of Medicine* 387 (5): 468–70. <https://doi.org/10.1056/NEJMc2207519>.
- Wang, Qian, Yicheng Guo, Sho Iketani, Manoj S. Nair, Zhiteng Li, Hiroshi Mohri, Maple Wang, et al. 2022. « Antibody Evasion by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4 and BA.5 ». *Nature* 608 (7923): 603–8. <https://doi.org/10.1038/s41586-022-05053-w>.

Figure caption:

Figure 1: SARS-CoV-2 (Omicron variant) infection severity criteria according to vaccine status in the three age classes. A: Extension of lung lesions on CT scanner; B: hospitalisation cause; C: Proportion of patients requiring oxygen; D: Maximal oxygen flow; E: Duration of oxygen therapy; F: Proportion of patients requiring ICU and G: Proportion of death at day 28.

Tables

Table 1: Characteristics of patients with SARS-CoV-2 (Omicron variant) infection according to vaccinal status: Demographics, underlying diseases and presentation

	Vaccinated (N=746)	Unvaccinated (N=469)	p-value	
Age (years) n (%)			0.300	
	<35y	67 (9.0)	54 (11.5)	
	35-65y	198 (26.5)	128 (27.3)	
	>65y	481 (64.5)	287 (61.2)	
Age (years)	74.0 [57.3-85.0]	71.0 [55.0-83.0]	0.041	
Gender: men n (%)	406 (54.4)	217 (46.3)	0.007	
Body Mass Index (kg/m ²)	25.9 [22.2-29.4] _(n=391)	26.1 [22.6-29.2] _(n=232)	0.670	
Overweight (BMI>25) n (%)	221 (56.5) _(n=391)	134 (57.8) _(n=232)	0.828	
Pre-existing comorbidities n (%)				
	Cardiac failure	121 (23.6) _(n=512)	65 (18.3) _(n=355)	0.073
	Respiratory disease	103 (13.8)	47 (10.0)	0.062
	Oxygen at home	15 (2.9) _(n=514)	3 (0.8) _(n=354)	0.063
	Kidney failure (GFR<30)	88 (12.0) _(n=731)	31 (6.8) _(n=459)	0.004
	Diabetes	184 (24.7)	106 (22.7)	0.452
	Hypertension	261 (50.8) _(n=514)	183 (51.5) _(n=355)	0.877
	Solid cancer < 3 months	22 (3.0) _(n=745)	9 (1.9)	0.351
	Hematologic malignancy	42 (5.6)	10 (2.1) _(n=468)	0.003

Immunodepression	77 (15.0) _(n=514)	33 (9.3) _(n=355)	0.013
At least one comorbidity among the above	523 (70.1)	330 (70.4)	0.949
Number of comorbidities	1.0 [0.0; 2.0]	1.0 [0.0; 2.0]	0.201
Tobacco, active or discontinued < 3 years, n (%)	44 (11.9) _(n=370)	38 (15.4) _(n=247)	0.258
Previous SARS-CoV-2 infection n (%)	12 (1.9) _(n=633)	10 (2.4) _(n=415)	0.661
Time from a previous infection (days)	319.0 [43.0; 344.0] _(n=9)	215 [97.3; 389.5] _(n=10)	0.497
Time from last vaccine dose (days)	113.0 [64.0; 178.2]	-	-
Admission for COVID-19	359 (48.7) _(n=737)	317 (69.5) _(n=456)	<0.001
Ct value (lowest value if many)	21.4 [18.2; 27.0] _(n=423)	22.1 [19.0; 27.3] _(n=273)	0.125
CRP (highest value) (mg/L)	58.0 [21.5; 117.5] _(n=575)	66.0 [26.0; 126.3] _(n=380)	0.110
Proportion of lung involved on CT scan n (%)	n=179	n=168	0.003
	0-10%	90 (50.3)	51 (30.4)
	11-25%	40 (22.3)	55 (32.7)
	26-50%	32 (17.9)	41 (24.4)
	51-75%	12 (6.7)	18 (10.7)
	>75%	5 (2.8)	3 (1.8)

Quantitative variables are presented as median (1st quartile - 3rd quartile). When data were missing, or calculation is performed on a subgroup, the number of patients out of whom the statistic was calculated is mentioned alongside.

Table 2: Characteristics of patients with SARS-CoV-2 (Omicron variant) infection according to vaccinal status: Management and outcomes during hospital stay

	Vaccinated (N=746)	Unvaccinated (N=469)	p-value
Requirement for oxygen n (%)	385 (51.6)	304 (64.8)	<0.001
Maximal oxygen flow (L/min)	4.0 [2.0; 10.0]	7.0 [3.0; 15.0]	<0.001
Duration of oxygen therapy (days)	5.0 [2.0; 10.0]	7.0 [4.0; 11.8]	<0.001
High-flow oxygen n (%)	32 (4.4) _(n=729)	56 (12.0) _(n=468)	<0.001
Steroid therapy			
prescribed n (%)	297 (40.0) _(n=743)	275 (58.8) _(n=468)	<0.001
dose median (IQR)	7.5 [6.0; 11.1] _(n=290)	8.0 [6.0; 12.0] _(n=273)	0.009
duration (days)	5.0 [3.0; 10.0] _(n=286)	8.0 [4.0; 10.0] _(n=272)	<0.001
Tocilizumab n (%)	20 (2.7) _(n=745)	29 (6.2)	0.004
Monoclonal Ab n (%) [¥]	30 (4.0) _(n=745)	19 (4.1) _(n=467)	1.000
Antiviral use n (%) [§]	27 (5.2) _(n=516)	25 (7.0) _(n=355)	0.336
ICU admission n (%)	60 (8.0)	72 (15.4)	<0.001
ICU duration (days)	7.0 [3.0; 15.0]	9.0 [5.0; 15.0]	0.095
Invasive mechanical ventilation n (%)	17 (2.3) _(n=740)	22 (4.7) _(n=464)	0.030
Invasive mechanical ventilation duration (days)	5.0 [2.5; 12.5]	8.0 [7.0; 20.0]	0.037
Death at day 28 n (%)	71 (9.5)	62 (13.2)	0.044
Death at day 28 and/or ICU admission n, (%)	113 (15.2)	116 (24.7)	<0.001
Length of stay (days)	7.0 [3.0; 14.0] _(n=571)	8.0 [4.0; 13.0] _(n=377)	0.472

Quantitative variables are presented as median (1st quartile - 3rd quartile). When data were missing the number of patients out of whom the percentage was calculated is mentioned alongside the percentage.

¥ Among the 30 vaccinated patients who received monoclonal antibodies, 55.6%, 3.7% and 40.7% received Evusheld, Sotrolizumab and Xevudy respectively. Among the 19 non vaccinated patients, 85.7% and 14.3% received Evusheld and Xevudy respectively.

§ Among the 27 vaccinated patients who received antiviral, 78.6% received Remdesivir and 21.4% favipravir. Among the 25 unvaccinated patients who received an antiviral, 57.7% received remdesivir and 42.3% received favipravir.

Table 3: Association of patient characteristics with negative outcomes (bivariate logistic regression)

Factors	Death at day 28		ICU		Oxygen required	
	OR (IC95%)	p-value	OR (IC95%)	p-value	OR (IC95%)	p-value
Age (years)	1.05 [1.04; 1.07]	<0.001	1.00 [0.99; 1.00]	0.306	1.03 [1.02; 1.04]	<0.001
Gender: Male	1.14 [0.79; 1.64]	0.485	1.48 [1.03; 2.14]	0.038	1.38 [1.10; 1.73]	0.006
Diabetes mellitus	1.55 [1.04; 2.28]	0.028	1.64 [1.10; 2.40]	0.014	1.31 [1.00; 1.72]	0.048
Hypertension	1.47 [0.97; 2.27]	0.073	1.21 [0.80; 1.83]	0.365	1.87 [1.43; 2.45]	<0.001
Tobacco	1.44 [0.66; 2.87]	0.323	1.53 [0.67; 3.14]	0.278	1.16 [0.72; 1.85]	0.546
BMI (kg/m ²)	0.94 [0.89; 0.99]	0.037	1.05 [1.00; 1.09]	0.029	1.07 [1.04; 1.10]	<0.001
Overweight (BMI>25)	0.54 [0.30; 0.97]	0.040	1.44 [0.83; 2.59]	0.207	1.71 [1.24; 2.36]	0.001
Kidney failure (GFR<30)	2.86 [1.77; 4.53]	<0.001	2.11 [1.26; 3.42]	0.003	1.81 [1.21; 2.75]	0.005
Respiratory disease	1.67 [1.01; 2.66]	0.036	1.40 [0.83; 2.27]	0.189	3.06 [2.06; 4.64]	<0.001
Oxygen at home	0.97 [0.15; 3.48]	0.968	1.48 [0.34; 4.59]	0.539	15.04 [3.07; 271.60]	0.009
Cardiac failure	1.71 [1.06; 2.69]	0.024	1.39 [0.86; 2.19]	0.167	1.58 [1.14; 2.22]	0.007
Solid cancer < 3 months	5.54 [2.56; 11.57]	<0.001	0.88 [0.21; 2.51]	0.829	1.06 [0.52; 2.23]	0.874
Hematologic malignancy	2.29 [1.09; 4.42]	0.019	0.49 [0.12; 1.36]	0.236	1.34 [0.76; 2.43]	0.314
Immunosuppression	1.64 [0.92; 2.80]	0.082	1.28 [0.70; 2.22]	0.397	1.23 [0.82; 1.85]	0.318
At least one comorbidity	1.52 [1.00; 2.36]	0.055	1.93 [1.25; 3.11]	0.004	1.65 [1.29; 2.11]	<0.001
Number of comorbidities	1.26 [1.11; 1.42]	<0.001	1.20 [1.06; 1.36]	0.003	1.20 [1.10; 1.30]	<0.001
Previous SARS-CoV-2 infection	0.40 [0.05; 2.98]	0.368	0.42 [0.06; 3.17]	0.402	0.81 [0.35; 1.90]	0.630
Time from last infection (days) [£]		1.000		0.997		0.739
Vaccination	0.69 [0.48; 0.99]	0.045	0.48 [0.33; 0.69]	<0.001	0.58 [0.46; 0.73]	<0.001
Time from last vaccine injection (days) [£]		0.289		0.117		0.104

£: For the time from last infection, and from last vaccine injection, the scarcity of data made the calculation of confidence intervals irrelevant.

Table 4: Factors associated with negative outcomes, with a multivariate logistic regression (best model according to AIC).

	Death on day 28		ICU		Need for oxygen	
	Best model	p-value	Best model	p-value	Best model	p-value
Age	1.06 [1.04; 1.08]	<0.001			1.03 [1.02; 1.03]	<0.001
Gender: Male			1.25 [0.82; 1.90]	0.304	1.37 [1.02; 1.83]	0.036
Diabetes			1.51 [0.95; 2.36]	0.076		
Kidney failure	2.52 [1.44; 4.31]	0.001	2.30 [1.29; 3.97]	0.004		
Previous SARS-CoV-2 infection	0.29 [0.02; 1.59]	0.247	0.36 [0.02; 1.81]	0.325		
Vaccination	0.50 [0.32; 0.77]	0.002	0.40 [0.26; 0.62]	<0.001	0.34 [0.25; 0.46]	<0.001
Pulmonary diseases	1.51 [0.86; 2.56]	0.138	1.68 [0.96; 2.85]	0.060	1.91 [1.19; 3.12]	0.009
O ₂ at home					8.41 [1.58; 156.23]	0.044
Solid cancer for < 3 months	7.99 [2.97; 20.80]	<0.001				
Haematological cancer	3.84 [1.67; 8.29]	0.001				
Immunosuppressed					1.58 [1.03; 2.46]	0.038

Models were explored with a full model including the variable "gender", "Age", "Diabetes", "HTA", "KidneyFailure", "O2_home", "CardiacFailure", "ImmunoSup", "previousSARS-CoV-2 infection", "Vaccination", "PulmDis", "SolidCancer3M", "HematoK", "OneComorb". "Tobacco", "BMI", "overweight" were not included due to more than 50% of missing data. No interactions were found.

Table 5: Comparison of the Omicron infection with the Delta infection according to vaccination status: Demographics, underlying diseases and presentation.

	Vaccinated (N=1220)			Unvaccinated (N=950)		
	Omicron (n=746)	Delta (n=474)	p-value	Omicron (n=469)	Delta (n=481)	p-value
Age (years) n (%)			0.031			<0.001
<35y	67 (9.0)	27 (5.7)		54 (11.6)	97 (20.2)	
35-65y	198 (26.6)	111 (23.4)		128 (27.4)	225 (46.8)	
>65y	481 (64.5)	336 (70.9)		287 (61.2)	159 (33.1)	
Age (years)	74.0 [57.3; 85.0]	75.0 [63.3; 84.0]	0.012	71.0 [55.0; 83.0]	55.0 [38.0; 73.0]	<0.001
Gender: men n (%)	406 (54.4)	261 (55.1)	0.873	217 (46.3)	223 (46.4)	1.000
Body Mass Index (kg/m ²)	25.9 [22.2; 29.4]	25.8 [22.3; 31.1]	0.036	26.1 [22.6; 29.2]	27.2 [24.2; 31.2]	<0.001
Overweight (BMI>25) n (%)	221 (56.5)	192 (56.6)	1.000	134 (57.8)	222 (69.4)	0.006
Pre-existing comorbidities n (%)						
Cardiac failure	121 (23.6)	50 (13.7)	<0.001	65 (18.3)	29 (8.0)	<0.001
Respiratory disease	103 (13.8)	91 (20.7)	0.002	47 (10.0)	54 (12.6)	0.256
Oxygen at home	15 (2.9)	14 (4.0)	0.515	3 (0.8)	5 (1.4)	0.501
Kidney failure (GFR<30)	88 (12.0)	51 (15.2)	0.182	31 (6.8)	10 (3.2)	0.041
Diabetes	184 (24.7)	127 (28.7)	0.141	106 (22.6)	76 (17.8)	0.086
Hypertension	261 (50.8)	244 (55.1)	0.206	183 (51.5)	123 (28.7)	<0.001
Solid cancer < 3 months	22 (3.0)	17 (4.8)	0.170	9 (1.9)	8 (2.2)	0.945
Hematologic malignancy	42 (5.6)	25 (7.1)	0.428	10 (2.1)	6 (1.7)	0.869
Immunodepression	77 (15.0)	74 (20.3)	0.048	33 (9.3)	21 (5.8)	0.110
At least one comorbidity among those above	523 (70.1)	369 (90.4)	<0.001	330 (70.4)	306 (86.9)	<0.001
Number of comorbidities	1.0 (0.0; 2.0]	2.0 [1.0; 3.0]	<0.001	1.0 [0.0; 2.0]	1.0 [0.0; 2.0]	0.010

Tobacco, active or discontinued < 3 years, n (%)	44 (11.9)	36 (10.3)	0.580	38 (15.4)	49 (14.3)	0.800
Previous SARS-CoV-2 infection n (%)	12 (1.9)	19 (5.4)	0.005	10 (2.4)	12 (3.4)	0.533
Time from a previous infection (days)	319.0 [43.0; 344.0]	226.0 [176.5; 299.0]	0.688	215.0 [97.3; 389.5]	69 [43.3; 244.3]	0.113
Time from last vaccine dose (days)*	113.0 [64.0; 178.2]	125.0 [82.0; 166.5]	0.716	-	-	-
Admission for COVID-19	359 (48.7)	281 (59.3)	<0.001	317 (69.5)	361 (75.1)	0.069
Ct value (lowest value if many)	21.4 [18.2; 27.0]	26.0 [18.0; 34.0]	<0.001	22.1 [19.0; 27.3]	26.0 [21.0; 33.0]	<0.001
CRP (highest value) (mg/L)	58.0 [21.5; 117.5]	87.5 [31.3; 152.8]	<0.001	66.0 [26.0; 126.3]	86.0 [34.0; 145.0]	0.073
Proportion of lung involved on CT scan n (%)			0.134			<0.001
0-10%	90 (50.3)	67 (36.8)		51 (30.4)	31 (13.5)	
11-25%	40 (22.3)	50 (27.5)		55 (32.7)	57 (24.9)	
26-50%	32 (17.9)	39 (21.4)		41 (24.4)	75 (32.8)	
51-75%	12 (6.7)	18 (9.9)		18 (10.7)	49 (21.4)	
>75%	5 (2.8)	8 (4.4)		3 (1.8)	17 (7.4)	

Table 6: Comparison of the Omicron infection with the Delta infection according to vaccinal status: Management and outcomes during hospital stay.

	Vaccinated (N=1220)			Unvaccinated (N=950)		
	Omicron (n=746)	Delta (n=474)	p-value	Omicron (n=469)	Delta (n=481)	p-value
Requirement for oxygen n (%)	385 (51.6)	229 (57.5)	0.064	304 (64.8)	270 (73.0)	0.014
Maximal oxygen therapy (L/min)	3.0 [1.0; 9.0]	3.0 [0.0; 8.8]	0.140	6.0 [2.0; 15.0]	6.0 [2.0; 50.0]	0.153
Duration of oxygen therapy (days)	3.0 [0.5; 7.3]	3.0 [0.0; 8.0]	0.369	6.0 [2.0; 10.0]	6.0 [2.0; 12.0]	0.629
High-flow oxygen n (%)	32 (4.4)	49 (13.6)	<0.001	56 (12.0)	105 (29.4)	<0.001
Steroid therapy prescribed n (%)	297 (40.0)	174 (47.2)	0.027	275 (58.8)	250 (68.5)	0.005
dose median (IQR)	7.5 [6.0; 10.7]	6.0 [6.0; 7.5]	<0.001	8.0 [6.0; 12.0]	6.0 [6.0; 9.0]	<0.001
duration (days)	5.0 [3.0; 10.0]	9.0 [5.0; 10.0]	<0.001	8.0 [4.0; 10.0]	10.0 [7.0; 10.0]	<0.001
Tocilizumab n (%)	20 (2.7)	21 (6.3)	0.007	29 (6.2)	59 (18.3)	<0.001
Monoclonal Ab n (%)	30 (4.0)	27 (7.3)	0.030	19 (4.1)	7 (1.9)	0.122
ICU admission n (%)	60 (8.0)	60 (16.2)	<0.001	72 (15.4)	133 (36.0)	<0.001
Invasive mechanical ventilation n (%)	17 (2.3)	25 (6.9)	<0.001	22 (4.7)	59 (16.5)	<0.001
Death at day 28 n (%)	71 (9.5)	74 (16.7)	<0.001	62 (13.2)	53 (12.2)	0.733
Death at day 28 and/or ICU admission n, (%)	113 (15.1)	116 (30.7)	<0.001	116 (24.7)	166 (44.6)	<0.001
Length of stay	7.0 [3.0; 14.0]	9.0 [4.0; 16.0]	0.003	8.0 [4.0; 13.0]	7.0 [3.0; 15.0]	0.866







Table 7: Multivariate analysis on the merged cohort (delta + omicron).

	Death on day 28		ICU		Need for oxygen	
	Best model	p-value	Best model	p-value	Best model	p-value
Variant: Omicron	0.53 [0.37; 0.76]	0.001	0.19 [0.12; 0.28]	<0.001	0.50 [0.38; 0.67]	<0.001
Gender: Male	1.66 [1.15; 2.41]	0.007	1.37 [0.96; 1.95]	0.084	1.65 [1.25; 2.18]	<0.001
Age	1.07 [1.05; 1.08]	<0.001			1.04 [1.03; 1.04]	<0.001
Kidney failure	2.32 [1.46; 3.67]	<0.001	0.41 [0.15; 0.93]	0.050		
HTA	1.28 [0.87; 1.90]	0.211				
Immunosuppressed	2.21 [1.30; 3.66]	0.003	0.79 [0.31; 1.83]	0.593	1.56 [1.05; 2.33]	0.028
Previous SARS-CoV-2 infection	0.14 [0.01; 0.67]	0.053	0.10 [0.01; 0.50]	0.028	0.08 [0.02; 0.26]	<0.001
Vaccination	0.45 [0.30; 0.66]	<0.001	0.26 [0.17; 0.39]	<0.001	0.20 [0.14; 0.28]	<0.001
Solid Cancer < 3 months	5.61 [2.53; 12.57]	<0.001	0.41 [0.09; 1.31]	0.174		
Overweight			1.72 [1.10; 2.77]	0.021	1.63 [1.17; 2.27]	0.004
At least one comorbidity			1.68 [0.84; 3.45]	0.146	1.61 [0.97; 2.67]	0.064
O2 treatment at home					2.86 [1.05; 9.28]	0.053
Interaction vaccination x Immunosuppressed *			2.95 [1.03; 8.87]	0.047		
Interaction vaccination x Previous COVID-19*					5.60 [1.21; 28.49]	0.030

In the model for ICU, a significant and positive interaction was found between being vaccinated and being immunosuppressed, which means that the protective effect of vaccination on the risk of ICU admission decreases among immunosuppressed patients.

In the model for O₂ need, a significant and positive interaction was found between being vaccinated and having a previous SARS-CoV-2 infection, which means that effect of vaccination was decreased among patients having previously had SARS-CoV-2 infection. In addition, a

trend toward interaction between being vaccinated and being immunosuppressed was found, similarly to the ICU model, but was not significant ($p=0.08$), which suggests an effect comparable to the ICU model.

A: Pulmonary involment**B: Hospitalisation cause****C: Oxygen requirement****D: Max O2 flow****E: O2 duration****F: Patients requiring ICU****G: Death at day 28**